ATE466106T1 - Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen - Google Patents

Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen

Info

Publication number
ATE466106T1
ATE466106T1 AT04765894T AT04765894T ATE466106T1 AT E466106 T1 ATE466106 T1 AT E466106T1 AT 04765894 T AT04765894 T AT 04765894T AT 04765894 T AT04765894 T AT 04765894T AT E466106 T1 ATE466106 T1 AT E466106T1
Authority
AT
Austria
Prior art keywords
diagnosis
diseases associated
spondines
futrins
compositions
Prior art date
Application number
AT04765894T
Other languages
English (en)
Inventor
Christof Niehrs
Wei Wu
Andrei Klinka
Olga Kazanskaya
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34486059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE466106(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE466106T1 publication Critical patent/ATE466106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04765894T 2003-10-10 2004-10-08 Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen ATE466106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023000 2003-10-10
PCT/EP2004/011269 WO2005040418A2 (en) 2003-10-10 2004-10-08 Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt

Publications (1)

Publication Number Publication Date
ATE466106T1 true ATE466106T1 (de) 2010-05-15

Family

ID=34486059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765894T ATE466106T1 (de) 2003-10-10 2004-10-08 Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen

Country Status (11)

Country Link
US (8) US9081011B2 (de)
EP (3) EP2093298A3 (de)
AT (1) ATE466106T1 (de)
CY (1) CY1114679T1 (de)
DE (1) DE602004026898D1 (de)
DK (2) DK1673475T3 (de)
ES (2) ES2345256T3 (de)
PL (1) PL2157192T3 (de)
PT (1) PT2157192E (de)
SI (1) SI2157192T1 (de)
WO (1) WO2005040418A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
DK1673475T3 (da) 2003-10-10 2010-07-19 Deutsches Krebsforsch Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
CA2554403A1 (en) * 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
SI2081586T2 (sl) * 2006-10-20 2019-01-31 Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts Rspondini kot modulatorji angiogeneze in vaskulogeneze
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
PL3009148T3 (pl) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
AU2013203352B2 (en) * 2007-07-02 2016-10-27 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP3441458B9 (de) 2009-02-03 2023-08-23 Koninklijke Nederlandse Akademie van Wetenschappen Nährmedium für epithelstammzellen und organelle mit den besagten stammzellen
EP2412800A1 (de) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Leberorganoid, Verwendungen davon und Kultivierungsverfahren zum Erhalten davon
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
WO2010121923A1 (en) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
EP2494349A4 (de) * 2009-09-29 2013-08-07 Dart Neuroscience Cayman Ltd Gene, verfahren und zusammensetzungen in zusammenhang mit neurogenese und ihrer modulation
EP2977060A1 (de) * 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Rspo2- und rspo3-rezeptoren
CA2841745A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
CA2905830C (en) 2013-03-12 2022-01-18 Curegenix Inc. Quinazoline and naphthyridine derivatives useful in the treatment of cancer
MX2016004802A (es) 2013-10-18 2016-07-18 Genentech Inc Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP3193935A4 (de) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Behandlung von fibrotischen erkrankungen
WO2017095918A2 (en) * 2015-12-01 2017-06-08 Oncomed Pharmaceuticals, Inc. Methods for treating cancer using rspo3 antagonists
EP3443004A1 (de) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3-antikörper und verfahren zur verwendung
WO2018132572A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
CN110218740A (zh) * 2019-05-17 2019-09-10 深圳先进技术研究院 一种用于快速检测经典Wnt信号通路活性的脑血管内皮细胞系

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06504997A (ja) 1990-12-06 1994-06-09 アフィメトリックス，　インコーポレイテッド 非常に大きい規模の固定化されたポリマーの合成
US5322933A (en) 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
WO2003094843A2 (en) 2002-05-10 2003-11-20 Incyte Corporation Cell adhesion and extracellular matrix proteins
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
WO1998018947A1 (en) 1996-10-31 1998-05-07 Smithkline Beecham Corporation Methods for the characterization and selection of rna target motifs that bind compounds of pharmaceutical use
WO1998041539A2 (en) 1997-03-19 1998-09-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2001527403A (ja) 1997-04-25 2001-12-25 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
GB9828419D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel compounds
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
AU6181000A (en) 1999-07-29 2001-02-19 Chugai Research Institute For Molecular Medicine, Inc. Novel genes encoding protein kinase/protein phosphatase
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
US6653448B1 (en) * 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
AU5301201A (en) 2000-03-31 2001-10-15 Gen Hospital Corp Methods of modulating hair growth
WO2001077169A2 (en) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030022255A1 (en) 2000-12-22 2003-01-30 Morris David W. Novel compositions and methods for breast cancer
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
JP2005503108A (ja) * 2001-01-31 2005-02-03 インサイト・ゲノミックス・インコーポレイテッド タンパク質修飾およびメンテナンス分子
US20030165501A1 (en) 2001-02-16 2003-09-04 Genentech, Inc. Treatment involving Dkk-1 or antagonists thereof
US20100305003A1 (en) * 2001-03-05 2010-12-02 Arca Biopharma Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
EP1383789A2 (de) 2001-04-06 2004-01-28 Incyte Genomics, Inc. Mit zellwachstum, -differenzierung und -tod assoziierte proteine
WO2002100898A2 (en) 2001-06-11 2002-12-19 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2003027230A2 (en) 2001-08-03 2003-04-03 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
EP1427747B1 (de) 2001-08-30 2012-04-11 ARCA biopharma, Inc. Verfahren und materialien in verbindung mit stammzellen-wachstumsfaktor-ähnlichen polypeptiden und polynukleotiden
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2003025143A2 (en) 2001-09-19 2003-03-27 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Maxp1
US7439332B2 (en) 2002-04-26 2008-10-21 Kirin Pharma Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2004099408A1 (ja) 2003-05-09 2004-11-18 Research Association For Biotechnology 新規蛋白質およびそれをコードするｄｎａ
WO2005110009A2 (en) 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
DK1673475T3 (da) 2003-10-10 2010-07-19 Deutsches Krebsforsch Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
WO2005071058A2 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
CA2554403A1 (en) 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
WO2007013666A2 (en) 2005-07-26 2007-02-01 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
US7541431B2 (en) 2005-09-07 2009-06-02 Maine Medical Center Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (en) 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
SI2081586T2 (sl) 2006-10-20 2019-01-31 Deutsches Krebsforschungszentrum, Stiftung Des Oeffentlichen Rechts Rspondini kot modulatorji angiogeneze in vaskulogeneze
PL3009148T3 (pl) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
WO2010121923A1 (en) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
US20120165270A1 (en) 2009-04-27 2012-06-28 Yeon Sook Choi Inhibition of hair follicle growth by the wnt inhibitor dkk1
EP2977060A1 (de) 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Rspo2- und rspo3-rezeptoren
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
CA2841745A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof

Also Published As

Publication number Publication date
US20190194306A1 (en) 2019-06-27
EP2093298A2 (de) 2009-08-26
EP1673475A2 (de) 2006-06-28
US20140186917A1 (en) 2014-07-03
US20130337533A1 (en) 2013-12-19
CY1114679T1 (el) 2016-10-05
PT2157192E (pt) 2013-11-28
WO2005040418A3 (en) 2005-11-10
US20070244061A1 (en) 2007-10-18
WO2005040418A2 (en) 2005-05-06
ES2345256T3 (es) 2010-09-20
EP2093298A3 (de) 2009-09-23
US20160376349A1 (en) 2016-12-29
EP2157192B1 (de) 2013-08-28
US8921056B2 (en) 2014-12-30
DK2157192T3 (da) 2013-11-25
US8951745B2 (en) 2015-02-10
US20140357510A1 (en) 2014-12-04
EP1673475B1 (de) 2010-04-28
US9081011B2 (en) 2015-07-14
US20140134703A1 (en) 2014-05-15
DE602004026898D1 (de) 2010-06-10
PL2157192T3 (pl) 2014-01-31
SI2157192T1 (sl) 2013-11-29
US20140227713A1 (en) 2014-08-14
ES2437337T3 (es) 2014-01-10
DK1673475T3 (da) 2010-07-19
EP2157192A1 (de) 2010-02-24

Similar Documents

Publication Publication Date Title
ATE466106T1 (de) Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
DK0910647T3 (da) Human DNase i hyperaktive varianter
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE230416T1 (de) Neue mittel zur diagnose von gefässerkrankungen
ATE520710T1 (de) Polypeptide von leishmania major und dafür codierende polynukleotide, und deren anwendungen als impfstoffe, therapeutika und diagnostika
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
WO2004096856A3 (en) Secreted protein family
ATE378423T1 (de) Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie
BR0210401A (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento de um distúrbio ou de uma doença de um corpo de animal vivo, incluindo um humano
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
DE60043106D1 (de) Polypeptide und deren dna
DE69809785T2 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
BRPI0416507A (pt) polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, uso de um polipeptìdeo, uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira, composição farmacêutica, uso de um antagonista de citocina ou um agente anti-inflamatório, uso de polipeptìdeo,uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira,e um antagonista de citocina ou um agente anti-inflamatório, método de tratamento de uma doença em um paciente, e para a identificação de um composto e, animal transgênico não humano
ATE554393T1 (de) Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen
BRPI0408510A (pt) métodos de identificar um membro da famìlia secfam1, de diagnosticar e de tratar uma doença em um paciente, de monitorar o tratamento terapêutico de doença em um paciente, de identificar um composto, e de triar quanto a um composto eficaz para tratar doença, polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, uso de um polipeptìdeo, composição farmacêutica, composição de vacima, kit, e, animal não humano transgênico ou de abatimento
BR0210407A (pt) Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano
DE602004025017D1 (de) C1ckb-mutation als diagnostisches und therapeutisches ziel
ATE473295T1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
NO20052958L (no) Spleisevariant av humant placentalt veksthormon
DE50014417D1 (de) Nukleinsäure, die für ein protein der ctage-familie kodiert, deren verwendung und herstellung
SE0101317D0 (sv) Protein cluster v
WO2002097079A3 (en) Gene encoding molecular motor protein and diagnosis method for the disease related to the gene
BR0103257A (pt) Proteìnas antibióticas humanas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673475

Country of ref document: EP